Data / Drug companies / Guaifenesin, pseudoephedrine hydrochloride
Guaifenesin, pseudoephedrine hydrochloride: 8 companies and 8 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Guaifenesin, pseudoephedrine hydrochloride is listed in the FDA National Drug Code Directory by 8 companies, with 8 products in commercial distribution. 8 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, multilayer, extended release, and the newest product started marketing on April 2, 2026.
The request: Get every company that lists guaifenesin, pseudoephedrine hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 8
- Products
- 8
- Generic (ANDA) products
- 8 (100.0%)
- Application numbers
- 1
- Routes
- Oral
- Brand names
- Mucus Relief D, Mucus D, Mucus D, Leader Mucus Relief D, Foster and Thrive Mucus Relief D, Nasal and Chest Decongestant, Equate Mucus D
- openFDA record search
- api.fda.gov
Companies that list guaifenesin, pseudoephedrine hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| CVS Woonsocket Prescription Center, Incorporated | 1 | tablet, multilayer, extended release | Generic drugs (ANDA) | April 4, 2025 |
| Cardinal Health 110, LLC. DBA Leader | 1 | tablet, multilayer, extended release | Generic drugs (ANDA) | March 8, 2025 |
| H E B | 1 | tablet, multilayer, extended release | Generic drugs (ANDA) | November 30, 2023 |
| L. Perrigo Company | 1 | tablet, multilayer, extended release | Generic drugs (ANDA) | October 3, 2025 |
| Publix Super Markets Inc | 1 | tablet, multilayer, extended release | Generic drugs (ANDA) | April 2, 2026 |
| Strategic Sourcing Services LLC | 1 | tablet, multilayer, extended release | Generic drugs (ANDA) | November 20, 2024 |
| Walgreen Company | 1 | tablet, multilayer, extended release | Generic drugs (ANDA) | March 26, 2024 |
| Walmart Inc. | 1 | tablet, multilayer, extended release | Generic drugs (ANDA) | December 5, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, multilayer, extended release | 8 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 8 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Expectorant | 8 |
| alpha-Adrenergic Agonist | 8 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.